Anxiety and Depression Disorder in Patient Treated With rTPA for Mangment of Acute Ischemic Stroke

Study Overview
=================
Brief Summary
-----------------
In fact theWorld Health Organization estimates that 2-3% in general populations of countries across the world tend to be affected by severe mental disorders (1) Thrombolytic therapy seems to be of great importance in achieving better quality of life in ischemic stroke patients who respond to this therapy(rTPA).

Detailed Description
-----------------
There is a substantial body of evidenc suggesting a strong relation between neurotrophic factors and depression and anxiety pathogenesis (2,8) Brain-derived neurotrophic factor (BDNF), a member of the neurotrophic family known to regulate neuronal plasticity and survival , may play an important role in the pathophysiology of depression and anxiety (3,9). Different studies indicated patients who were exposed to traumatic events have anxiety comorbidity and lower levels of serum BDNF compared to those without a history of traumatic events (4) . BDNF has an antidepressant and anxiolytic effect which suggest that BDNF is implicated in the regulation of anxiety-related behaviors. which leads to a valine-to-methionine change in the proBDNF protein, was associated with lower activity-dependent secretion of BDNF (5)and has been implicated with increased susceptibility to neuropsychiatric disorders including depression, anxiety-related dysfunction, and bipolar disorder , all these studies suggest that BDNF is likely to be an important etiological factor in memory, depression and anxiety disorders (6,10). BDNF arises from a precursor, proBDNF, which is cleaved to produce the mature protein through the tissue plasminogen activator (tPA) pathway, and represents one mechanism that can regulate the action of BDNFarises from a precursor, proBDNF, which is cleaved to produce the mature protein through the tissue plasminogen activator (tPA) pathway, and represents one mechanism that can regulate the action of BDNF (7). The purpose of this study is to examine the quality of life after stroke of patients treated with thrombolysis .

Official Title
-----------------
Anxiety and Depression Disorder in Patient Treated With rTPA for Mangment of Acute Ischemic Stroke

Conditions
-----------------
Depression, Acute Stroke, Anxiety Disorders

Intervention / Treatment
-----------------
* Drug: Actilyse


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age more than 40. None of the pt had history of other psychiatric illness. male and female. Exclusion Criteria: 1-smoker. 2-substance abuser or dependence. 3-History of other psychiatric illness. 4-History of other neurological illness.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Actilyse|Infusion|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Detection and measureing anxiety and depressive symptoms in ischemic stroke patients treated with rtpA . | Hamilton depression and anxiety rating scale | 15 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measuring quality of life in patients with ischemic stroke treated wih rtpA . | Quality of life questionnaire | 10 minutes |